Eli Lilly has delivered roughly 700% returns over the past decade, leaving the S&P 500 in the dust and reshaping what investors expect from big pharma.
Ten years ago, Eli Lilly looked like a company slowly losing its edge. Patent expirations on blockbuster drugs like Cymbalta and Zyprexa had wiped billions from its revenue base, and Wall Street analysts openly questioned whether the Indianapolis-based drugmaker could survive as an independent entity. Today, Lilly is worth over $700 billion, making it the most valuable pharmaceutical company on the planet. The stock has returned approximately 700% since mid-2014, compared to roughly 180% for the S&P 500 over the same period.
According to figures referenced by Yahoo Finance, this performance places Lilly among the top-performing large-cap stocks in any sector over the past decade, not just healthcare. The question for investors now is whether the momentum is sustainable or whether the weight of expectations has finally outrun the fundamentals.
The reversal started with a disciplined approach to research that most competitors abandoned during the era of mega-mergers. While Pfizer and Merck were chasing acquisitions to replenish their pipelines, Lilly doubled down on internal drug development. The gamble paid off spectacularly with Trulicity, a diabetes medication that became the company's cash engine, generating over $7 billion in annual revenue at its peak before newer treatments started cannibalizing its market share.
What truly separated Lilly from every other pharmaceutical stock was the arrival of Mounjaro and, more recently, Zepbound. These GLP-1 receptor agonists do something previous generations of diabetes and weight-loss treatments never managed: they actually work well enough to shift clinical outcomes at a population level. Truluetypeptide, the active ingredient in both drugs, has shown efficacy that caught even bullish analysts off guard. Prescriptions have scaled faster than almost any drug class in modern history, and the addressable market keeps expanding as research identifies new potential applications, from sleep apnea to cardiovascular risk reduction.
The competitive dynamics here matter more than most earnings calls let on. Novo Nordisk currently shares the GLP-1 duopoly with Lilly, but manufacturing constraints have left both companies unable to meet demand. That sounds like a problem, but for investors it functions as a floor on revenue: there are billions in pent-up prescriptions that will convert to sales as production capacity comes online through 2025 and 2026.
Valuation Demands Flawless Execution
Lilly now trades at roughly 55 times forward earnings, a premium usually reserved for high-growth technology companies, not 148-year-old drugmakers. That multiple reflects confidence in a pipeline that includes donanemab for Alzheimer's disease, a treatment that could open an entirely new therapeutic frontier if regulatory approvals continue on track. The FDA granted traditional approval to Kisunla, Lilly's Alzheimer's drug, in mid-2024, making it the second disease-modifying therapy available for a condition affecting millions of Americans.
The risk is straightforward. Any clinical setback, manufacturing delay, or competitive threat from companies like Amgen or Viking Therapeutics, both developing next-generation obesity treatments, could trigger a significant repricing. The stock is priced for perfection in a business where setbacks are the norm, not the exception.
For long-term holders, the lesson is instructive. The best returns often come from companies that look broken, trading at depressed valuations when sentiment is at its worst. Lilly's decade-long run was built during years when headlines focused on patent cliffs and pipeline failures. The gains accrued to investors who understood that cyclical downturns in pharmaceutical research create the conditions for outsized returns when breakthroughs finally arrive.
Watch the first-quarter 2025 earnings call closely. Management's commentary on Zepbound prescription trends and donanemab rollout timelines will signal whether the next decade can approach anything close to what the previous one delivered. The stock has already priced in a lot of good news. The question is whether it has priced in enough bad news to protect investors if the science stops cooperating.
